title: Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
abstract: Progestogens are the first drugs to demonstrate reproducibly a reduction in the rate of early preterm birth. The efficacy and safety of progestogens are related to individual pharmacologic properties of each drug within this class of medication and characteristics of the population that is treated. The synthetic 17-hydroxyprogesterone caproate and natural progesterone have been studied with the use of a prophylactic strategy in women with a history of preterm birth and in women with a multiple gestation. Evidence from a single large comparative efficacy trial suggests that vaginal natural progesterone is superior to 17-hydroxyprogesterone caproate as a prophylactic treatment in women with a history of mid-trimester preterm birth. Progestogen therapy is indicated for women with this highest risk profile based on evidence from 2 trials. A therapeutic approach based on the identification of a sonographic short cervix has been studied in several phase III trials. Independent phase III trials and an individual patient metaanalysis suggest that vaginal progesterone is efficacious and safe in women with a singleton and a short cervix. Two trials that tested 17-hydroxyprogesterone caproate in women with a short cervix showed no benefit. No consistent benefit for the prophylactic or therapeutic use of progestogens has been demonstrated in larger trials of women whose pregnancies were complicated by a multiple gestation (twins or triplets), preterm labor, or preterm rupture of membranes. Unfortunately, several large randomized trials in multiple gestations have identified harm related to 17-hydroxyprogesterone caproate exposure, and the synthetic drug is contraindicated in this population. The current body of evidence is evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines to derive the strength of recommendation in each of these populations. A large confirmatory trial that is testing 17-hydroxyprogesterone caproate exposure in women with a singleton pregnancy and a history of preterm birth is near completion. Additional study of the efficacy and safety of progestogens is suggested in well-selected populations based on the presence of biomarkers.
authors.affiliation: University of Kentucky, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Lexington, KY. Electronic address: john.obrien2@uky.edu.
authors.forename: John M
authors.initials: JM
authors.lastname: O'Brien
authors.affiliation: University of South Alabama, Department of Obstetrics and Gynecology, Mobile, AL.
authors.forename: David F
authors.initials: DF
authors.lastname: Lewis
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D000282:Administration, Intravaginal; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D011374:Progesterone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011372:Progestins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D006908:Hydroxyprogesterones; D011372:Progestins; D000077713:17 alpha-Hydroxyprogesterone Caproate; D011374:Progesterone
keywords: 17-OHPC; adverse event; biomarker; cervical length; early preterm birth; history of preterm birth; metaanalysis; multiple gestation; pharmacodynamics; progestogens; safety; short cervix; twin gestation